Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, ...

On this weeks episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on ...

What does strategy look like for a drug development program? The word strategy can mean different things to different individuals. If you polled a group on a development team, you may receive ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

IN 2017, SAQIB ISLAM FOUND HIMSELF FACING ONE OF THOSE PIVOTAL CAREER DECISIONS — LEAVE A GOOD JOB AT A GOOD COMPANY FOR THE CHANCE TO GROW A FLEDGLING STARTUP. He was only a year into his job as ...

Managing third-party risk is one of the most arduous challenges facing pharmaceutical companies, and regulatory requirements are just one piece of this puzzle. Pharmaceutical organizations are ...

In the United States, it has typically taken 10 to 15 years for breakthrough research to be adopted in real-world clinical settings: a decade or more between proving something saves lives and actually ...